Sun Pharma gets DCGI nod to market generic semaglutide injection

Key Highlights

• The product has received approval from the DCGI following a review of a Phase III clinical trial conducted in India, it added.
• Noveltreat will be available in five dose strengths — 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, with a maintenance dose of 2.4 mg once weekly, it said.
• The product is administered via an easy-to-use prefilled pen, designed for convenient, accurate dosing.
• “Obesity and diabetes have emerged as two of the most pressing health challenges confronting India, and GLP-1-based therapies can play a meaningful role in addressing this growing burden.
• Noveltreat meets global quality standards and is supported by robust Indian clinical evidence on efficacy and safety for weight management,” Sun Pharma MD Kirti Ganorkar stated.